Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?-Reference-Cited by-同舟云学术

Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?

Published:2020-09-18 Issue:2 Volume:73 Page:336-340
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Anderson Evan J¹²³^ORCID,Campbell James D⁴,Creech C Buddy⁵,Frenck Robert⁶,Kamidani Satoshi¹³,Munoz Flor M⁷⁸,Nachman Sharon⁹,Spearman Paul⁶^ORCID

Affiliation:

1. Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA

2. Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

3. Center for Childhood Infections and Vaccines, Children’s Healthcare of Atlanta, Atlanta, Georgia, USA

4. Department of Pediatrics and Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA

5. Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

6. Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio,USA

7. Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA

8. Department of Molecular Virology and Microbiology, Baylor College of Medicine , Houston, Texas, USA

9. Department of Pediatrics, The State University of New York (SUNY) Stony Brook; Stony Brook, New York, USA

Abstract

Abstract While adult clinical trials of coronavirus disease 2019 (COVID-19) vaccines have moved quickly into phase 3 clinical trials, clinical trials have not started in children in the United States. The direct COVID-19 impact upon children is greater than that observed for a number of other pathogens for which we now have effective pediatric vaccines. Additionally, the role of children in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission has clearly been underappreciated. Carefully conducted phase 2 clinical trials can adequately address potential COVID-19 vaccine safety concerns. Delaying phase 2 vaccine clinical trials in children will delay our recovery from COVID-19 and unnecessarily prolong its impact upon children’s education, health, and emotional well-being, and equitable access to opportunities for development and social success. Given the potential direct and indirect benefits of pediatric vaccination, implementation of phase 2 clinical trials for COVID-19 vaccines should begin now.

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa1425/37549926/ciaa1425.pdf

Reference53 articles.

1. SARS-CoV-2 mRNA vaccine development enabled by prototy;Corbett;bioRxiv,2020

2. A SARS-CoV-2 mRNA vaccine—preliminary report [reply];Jackson;N Engl J Med,2020

3. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report;Mulligan;medRxiv,2020

4. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial;Folegatti;Lancet,2020

5. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study;Walsh;medRxiv,2020

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of COVID-19 childhood and adolescent vaccination on mortality in Argentina;Vaccine;2024-09

2. Risk of COVID-19 in Children throughout the Pandemic and the Role of Vaccination: A Narrative Review;Vaccines;2024-08-29

3. The affecting factors of COVID‐19 vaccine hesitancy in parents of children with cancer: A cross‐sectional Jordanian study;Immunity, Inflammation and Disease;2024-07

4. Vaccine Development;Pediatric Clinics of North America;2024-06

5. U.S. Parental Vaccine Hesitancy and the COVID-19 Vaccine: A Scoping Review;The Journal of School Nursing;2024-05-16